Johnson & Johnson (JNJ) Posts Earnings Results

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02, Bloomberg Earnings reports. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same period last year, the company posted $1.58 EPS. The business’s revenue was up 11.5% on a year-over-year basis. Johnson & Johnson updated its FY18 guidance to $8.00-8.20 EPS.

Shares of Johnson & Johnson (JNJ) opened at $148.14 on Tuesday. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $148.32. The firm has a market cap of $397,980.00, a PE ratio of 25.72, a P/E/G ratio of 2.76 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.27%. Johnson & Johnson’s payout ratio is 58.33%.

Several equities research analysts have recently issued reports on JNJ shares. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a report on Thursday, January 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Citigroup raised their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $145.94.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Premier Asset Management LLC lifted its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after buying an additional 12 shares in the last quarter. LMR Partners LLP bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $2,784,000. Dupont Capital Management Corp lifted its holdings in Johnson & Johnson by 19.5% during the 2nd quarter. Dupont Capital Management Corp now owns 330,122 shares of the company’s stock valued at $43,672,000 after buying an additional 53,912 shares in the last quarter. QV Investors Inc. lifted its holdings in Johnson & Johnson by 6.7% during the 2nd quarter. QV Investors Inc. now owns 36,565 shares of the company’s stock valued at $4,837,000 after buying an additional 2,310 shares in the last quarter. Finally, S. R. Schill & Associates lifted its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. S. R. Schill & Associates now owns 10,494 shares of the company’s stock valued at $1,388,000 after buying an additional 40 shares in the last quarter. Institutional investors own 65.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Posts Earnings Results” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/23/johnson-johnson-jnj-posts-earnings-results.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply